KARIO MENOPAUSE
Food supplement declared in France, decision dated 31 October 2026
KARIO MENOPAUSE (KARIO) is a food supplement declared in France. Status: declared in France, may be marketed. 1 rule of use applies to its ingredients (limits and warnings).
- Brand
- KARIO
- Food business operator placing the product on the market
- DISTILLERIE DE LA SAINTE FAMILLE
- Status
- Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
- Form
- Bottle
- Daily dose
- 3cl
- Directions for use
- 1 dose par jour
- Intended populations
- General population, Men and women aged 18 and over, People over 60
- Not recommended (according to the manufacturer)
- Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, High blood pressure, Infants (under 1 year), Taking blood pressure medication, Children (under 6), Children (under 10)
- Objectives stated by the manufacturer (these are not authorised claims)
- Antioxidant, Menopause
Declaration 381019, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.
Declared composition
Plants
| Plant | Part | Preparation | Per day |
|---|---|---|---|
| Rubus idaeus L. | Feuille | Extrait fluide hydroglycériné | 600 mg |
| Alchemilla vulgaris L. | Parties aériennes | Extrait sec aqueux | 500 mg |
| Salvia sclarea L. | Feuille | Extrait fluide hydroglycériné | 200 mg |
| Citrus aurantium L. | Zeste | Macérât hydroalcoolique | 187.8 mg |
| Pimpinella anisum L. | Graine | Macérât hydroalcoolique | 75 mg |
| Mentha x piperita L. | Feuille | Macérât hydroalcoolique | 45 mg |
| Cinnamomum verum J. Presl | Ecorce | Macérât hydroalcoolique | 45 mg |
| Origanum majorana L. | Feuille | Macérât hydroalcoolique | 33.6 mg |
| Syzygium aromaticum (L.) Merr. & L.M.Perry | Bouton floral | Macérât hydroalcoolique | 22.53 mg |
| Juglans regia L. | Fruit | Macérât hydroalcoolique | 17.5 g |
List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).
Has the product changed? Photograph the packaging.
Label warnings
Les compléments alimentaires ne peuvent se substituer à une alimentation variée et équilibrée. Ne pas dépasser la dose journalière recommandée. Emploi déconseillé aux enfants, femmes enceintes ou allaitantes et en cas de traitement antihypertenseur. Réservé à l'adulte. Tenir hors de portée des enfants.
Regulatory points
- Conditions légales
Citrus aurantium L.: La quantité ingérée de p-synéphrine doit être inférieure à 20 mg par dose journalière recommandée. L'étiquetage doit comporter un avertissement déconseillant l'emploi aux enfants, aux femmes enceintes ou allaitantes et en cas de traitement anti-hypertenseur. La caféine et les sources de caféine ne sont pas autorisées dans les compléments alimentaires contenant Citrus aurantium L.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Mentha x piperita L.
Read the warning, when it applies and the studies cited
PEPPERMINT - MENTHA X PIPERITA
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have gallstones or anemia (Brinker 2010; Mills and Bone 2005; Blumenthal et al. 2000).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Condition of application: Essential oil.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have hiatus hernia or gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Known adverse reactions
Condition of application: Essential oil.
When using this product you may experience gastroesophageal reflux (Brinker 2010; Mills and Bone 2005; ESCOP 2003).
Sources cited by Health Canada (3)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
Stop use if hypersensitivity/allergy occurs (Mills and Bone 2005; ESCOP 2003).
Sources cited by Health Canada (2)
- ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
- Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
- Cinnamomum verum J. Presl
Read the warning, when it applies and the studies cited
Cinnamon - Cinnamomum Verum
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Blumenthal et al. 2000; WHO 1999).
Sources cited by Health Canada (4)
- Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): American Botanical Council. 2000.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
- WHO 1999: World Health Organization. WHO Monographs on Selected Medicinal Plants, Volume 1. Geneva (CH): World Health Organization; 1999.
- OMS 1999: Organisation mondiale de la santé (OMS). Monographs on Selected Medicinal Plants : Volume 1. Geneva (CHE) : Organisation mondiale de la santé.
Condition of application: All products except antioxidants.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Contraindications
Do not use if you are pregnant (Brinker 2010; BHC 2006; Blumenthal 2000).
Sources cited by Health Canada (3)
- Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): American Botanical Council. 2000.
- BHC 2006: Bradley PR, editor. British Herbal Compendium Volume 2: A Handbook of Scientific Information on Widely Used Plant Drugs—Companion to the British Herbal Pharmacopoeia. Bournemouth (GB): British Herbal Medicine Association; 2006.
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
Other declarations with the same name
In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.
- KARIO MENOPAUSE KARIO, declared in 2026 : different composition: 1 ingredient(s) added, 1 missing
Brand : KARIO
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.